Preparation method of (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1

background and overview[1] ezetimibe was jointly developed by schering-plough and merck for the treatment of hyperlipidemia. it was approved by the u.s. fda in 2002 under the trade name zetia. its chemical name is: 1-(4-fluorophenyl)-(3r)-[3-(4-fluorophenyl)-(3s)-hydroxypropyl]-(4s)-(4-hydroxyphenyl) -2-propionolactam. hyperlipidemia is an important risk factor for the occurrence of cardiovascular diseases such as atherosclerosis. lowering the total cholesterol…